Home / Guides / Semaglutide plateau
Stalled? Start with the timeline.
Semaglutide plateau: why weight loss stalls, and what to do next
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Weight loss on semaglutide slows and levels off over time; before week 17, a stall often just means your dose is still climbing (Wegovy label, checked November 1, 2026). At NexLife, a licensed provider can review your dose, and a higher one costs the same: $95 a month on the 12-month plan, or $109 month to month.
$95/mo on 12 months, every dosePrice Match Guarantee†
- Weeks 1 to 16? Your dose is still stepping up
- New vial? Check that your units match its strength
- Months in? Slower loss can still be progress

$95/mo on a 12-month plan, all-inclusive, same price at every dose
Or $109/mo month to month
Thinking about tirzepatide? $115 a month on the 12-month plan, $129 month to month
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $95 | $1,140 |
| 6-month | $99 | $1,188 |
| 3-month | $105 | $1,260 |
| Month to month | $109 | $1,308 |
Month to month costs $168 more over 12 months than the 12-month plan. Plans renew until you cancel. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout: $315, $594 or $1,140.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Compounded semaglutide and tirzepatide aren’t FDA-approved. A licensed provider prescribes one only when it offers a significant difference for you.
At a glance
Semaglutide plateau at a glance
The short answers. Each one is explained below.
| Question | Answer |
|---|---|
| When do plateaus show up? | Later than many expect. In Wegovy’s trials, average loss kept falling for months after the full dose and leveled off around week 60. |
| Stalled in weeks 1 to 16? | Not a plateau yet: the dose is still stepping up. On the label, 2.4 mg starts at week 17. |
| Started a new vial? | Check your units first. The same number of units can be a different dose. |
| Missed 2 or more doses in a row? | Tell your provider. The label says to restart the dose steps at a lower dose. |
| Who changes your dose? | Only your provider. Taking doses more often isn’t in the label. |
| Does a higher dose cost more at NexLife? | No. Compounded semaglutide is $95 a month on the 12-month plan, or $109 month to month, at every dose. |
Wegovy’s trials studied the FDA-approved medicine; compounded semaglutide wasn’t studied, and it isn’t FDA-approved. NexLife’s prices as of November 5, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Early stalls often aren’t plateaus: on the Wegovy label, the dose climbs until week 17, when 2.4 mg starts.
- Check the vial before the scale: units follow its strength, so a new strength needs new math.
- Missed doses count: miss 2 or more in a row, and the label says to restart the dose steps at a lower dose.
- Dose changes are your provider’s call. Taking doses more often isn’t in the label.
- Leveling off later is common: in Wegovy’s trials, average loss leveled off around week 60. Holding a weight you’re happy with is a result too.
- At NexLife, a higher dose costs the same: compounded semaglutide is $95 a month on the 12-month plan.
Quick check
Is semaglutide not working, or is it a plateau?
Start with where you are on the dose schedule. Most of the answer is there.
| Where you are | What it often means | What to do |
|---|---|---|
| Weeks 1 to 16the starting steps | Not a plateau yet. The label steps the dose up every 4 weeks: 0.25, 0.5, 1 and 1.7 mg. | Keep to your schedule. Your provider decides each step. |
| Weeks 17 to 68on 1.7 mg or 2.4 mg | Slower loss can still be progress. In STEP 4, people already on 2.4 mg lost another 7.9% on average between weeks 20 and 68. | Look at the trend over several weeks, not one weigh-in, and share it with your provider. |
| After week 68on the same dose | Leveling off is common. The 2-year average in STEP 5 was close to the 68-week average in STEP 1. | Ask your provider whether this is your maintenance weight, or whether a change makes sense. |
| After a new vial or a dose change | Check your units first. The same number of units can be a different dose. | Match your units to the strength on the new label before your next dose. |
| Weight creeping back up | Something other than a plateau: think missed doses, a break, or the vial itself. | Raise it with your provider, and check your vial’s dates: the FDA says to discard an opened vial within 28 days. |
Swipe the table sideways to see every column.
From the Wegovy prescribing information (revised June 2026) and the STEP 1, STEP 4 and STEP 5 trials, read Nov. 12, 2026. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
“Discard the vial within 28 days after the first use, even if medication remains in the vial.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
Trial data
When do semaglutide plateaus usually happen?
Later than many people expect. In Wegovy’s trials, average weight kept falling for months after the full dose and leveled off around week 60; two years in, the average loss was close to the 68-week figure.
The dose steps: 0.25, 0.5, 1 and 1.7 mg, 4 weeks each. On the label schedule, 2.4 mg starts at week 17.
In STEP 4, the 803 people who had reached 2.4 mg weighed about 10% less on average than at the start: 107.2 kg, down to 96.1 kg.
Those who kept taking it lost another 7.9% on average. Slower, but still going.
In STEP 1, the average was 14.9% below the starting weight, against 2.4% on placebo. 83.5% had lost at least 5%.
In STEP 5, a 2-year trial, the average was 15.2% below the start, against 2.6% on placebo: close to STEP 1’s 68-week figure. Its authors call the loss sustained: it leveled off after about week 60 and held to the end.
Different trials, different people. Setting STEP 1 at 68 weeks beside STEP 5 at 104 weeks is a rough comparison, but the numbers point one way: most of the loss came in the first 68 weeks, and two years in, the average was about the same.
On the Wegovy pill, 25 mg once a day, the OASIS 4 trial found an average of 13.6% at week 64.
An average isn’t you. In STEP 1, about 1 in 6 people lost less than 5% by week 68, while nearly a third lost 20% or more.
Figures from the Wegovy prescribing information (revised June 2026) and the published STEP 1, STEP 4, STEP 5 and OASIS 4 papers. People in every trial also had diet and activity support. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Why it stalls
Why does weight loss stall on semaglutide?
Some are part of how the medicine works. Others you can check today.
Your dose is still climbing
On the Wegovy label, weeks 1 to 16 are dose steps, 4 weeks each. The usual maintenance dose, 2.4 mg, starts at week 17. If a step doesn’t agree with you, the label says to consider waiting 4 weeks before the next one.
A new vial changed your units
Units follow the vial’s strength: units = dose in mg ÷ strength in mg/mL × 100 on a U-100 syringe. At 2.5 mg/mL, 2.4 mg is 96 units; at 5 mg/mL, it’s 48. Recheck every new label with our semaglutide dosage chart.
Missed or late doses
One missed dose: take it if your next one is more than 2 days away, otherwise skip it. Two or more missed in a row: the label says to restart the dose steps at a lower dose, to lower the risk of stomach side effects. Your provider picks that dose. Here’s how restarting works.
You’ve already lost a lot
A smaller body uses less energy, so the same habits take off less over time. That’s one reason loss slows even while the medicine keeps working.
Protein and muscle
Weight loss on a
GLP-1 can take muscle with it. A 2025 joint advisory from four groups in lifestyle medicine, obesity medicine and nutrition names muscle and bone loss among the challenges, and lists adequate protein and strength training to preserve lean mass. Meal ideas: what to eat on aGLP-1 .Sleep, stress and routine
The same advisory names activity, sleep and mental stress among the lifestyle factors that support long-term results.
Type 2 diabetes
In Wegovy’s label, average loss was 9.6% in the 68-week trial of adults with type 2 diabetes (3.4% on placebo), against 14.9% in STEP 1, without diabetes. The Wegovy pill’s trial on the label excluded people with type 2 diabetes.
Your dose may be your maintenance dose
On the label, 1.7 mg or 2.4 mg is the long-term dose, chosen by how you respond and how you feel on it. Holding a weight you’re happy with is a result too.
Label facts from the Wegovy prescribing information (revised June 2026). These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Step by step
How do you handle a semaglutide plateau?
Check what you can first, then talk to your provider. Six steps, in order.
- Check your week. In weeks 1 to 16, the dose is still stepping up; on the Wegovy label, 2.4 mg starts at week 17. A stall then often isn’t a plateau.
- Match your units to the vial. Units follow the strength on your vial’s label, so the same units can be a different dose. Redo the math with every new label.
- Count missed doses. On the label, one missed dose is taken if the next is more than 2 days away, otherwise skipped. Miss 2 or more in a row, and it says to restart the dose steps at a lower dose.
- Watch the trend. Look at your weight over several weeks, not one weigh-in. Slower loss can still be progress.
- Check protein, sleep and stress. A 2025 joint advisory lists adequate protein and strength training to preserve lean mass, and names activity, sleep and mental stress among the lifestyle factors that support long-term results.
- Talk to your provider. Have your current dose in milligrams, when you started it and your weight trend ready. Any dose change is your provider’s call.
The six steps above, in order. Your label and your prescriber’s instructions come first.
Your options
What can your provider change at a plateau?
Your provider weighs the options with you; nothing changes until they decide. Here are the levers.
The next step
If you’re still in the dose steps: the next dose, at least 4 weeks on, up to 2.4 mg.
A slower step
If a step brought side effects, the label suggests delaying the next one by 4 weeks.
A higher brand dose
On the Wegovy label, 7.2 mg (Wegovy HD) is an option once 2.4 mg has been tolerated for at least 4 weeks and more loss is clinically indicated. In the 72-week STEP UP trial, average loss was 18.8% on 7.2 mg and 15.5% on 2.4 mg.
Food and activity
Wegovy is approved alongside a reduced-calorie diet and more physical activity, and its trials coached both. A plan that covers protein and meals that sit well can help.
Holding steady
If you’ve reached a weight you and your provider are happy with, your current dose may simply become your maintenance dose.
Another medicine
Tirzepatide is one alternative. It means a new prescription, and Wegovy’s label advises against combining it with another
GLP-1 medicine. More below.
Leave dose changes to your provider. The FDA has received adverse event reports, some involving hospitalization, that may be linked to dosing errors with compounded semaglutide, and to doses beyond the label: taken more often or raised faster.
“FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products.”
U.S. Food and Drug Administration, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024)
STEP UP figures from the Wegovy prescribing information (revised June 2026). This trial studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Tirzepatide
Should you switch from semaglutide to tirzepatide after a plateau?
It’s one option a provider may raise, not the only one. Here’s what the head-to-head trial found, and what a switch involves.
The head-to-head trial
In SURMOUNT-5, adults with obesity and no type 2 diabetes lost 20.2% on average over 72 weeks on tirzepatide, against 13.7% on semaglutide, each at the highest dose they tolerated.
An average, not a promise
The trial compared starting each medicine; it didn’t test switching after a plateau. An average can’t tell you how you’d respond.
A new prescription
Tirzepatide starts with its own dose steps, and Wegovy’s label advises against using it with any other
GLP-1 medicine, tirzepatide included. Your provider sets the timing.
“Coadministration with other tirzepatide-containing products or with any
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026GLP-1 receptor agonist is not recommended.”
The head-to-head trial, published in The New England Journal of Medicine in 2025, was open-label and used FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
Dose and timing for a switch: semaglutide to tirzepatide. Already on tirzepatide and stalled? See tirzepatide plateau.
At NexLife
What does a semaglutide plateau cost at NexLife?
Nothing extra. Moving up a dose, or holding where you are, doesn’t change your monthly price.
| Plan | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| 12-month plan | $95 | $115 |
| 6-month plan | $99 | $119 |
| 3-month plan | $105 | $125 |
| Month to month | $109 | $129 |
Swipe the table sideways to see every column.
At NexLife, per month, all in, at every dose: the medication, a licensed provider, a nutrition plan, a 1:1 coaching call and free expedited shipping. No membership fee.
Already a member and stalled? Get in touch at
Next to the brand price list: Novo Nordisk lists self-pay Wegovy at a regular price of $349 a month from 0.25 mg to 2.4 mg, and Wegovy HD (7.2 mg) at $399 (checked Nov. 12, 2026). Compounded semaglutide isn’t FDA-approved; Wegovy is.
Vial math
How many units is your semaglutide dose?
It depends on your vial’s strength. Here are the Wegovy label’s dose steps at two example strengths.
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart. Or enter your own vial’s strength in the semaglutide dosage calculator.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $129/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Semaglutide plateau: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
How long does a semaglutide plateau last?
There’s no set length. In the first 16 weeks the dose is still climbing, so a stall may not be a plateau. Later, one can last as long as your dose and routine stay the same. In the 2-year STEP 5 trial of FDA-approved Wegovy, average loss leveled off after about week 60 and held: it was 15.2% at week 104.
Why did semaglutide stop working?
It may not have. Weight loss slows as you lose weight; in STEP 4, people on 2.4 mg were still losing between weeks 20 and 68, just more slowly. Missed doses, a new vial strength that changed your units, less protein, poor sleep or stress can also play a part. Your provider can review your dose and plan with you.
Should I increase my semaglutide dose?
Only if your provider says so. Wegovy’s label steps up every 4 weeks to a maintenance dose of 1.7 mg or 2.4 mg, and allows up to 7.2 mg once 2.4 mg has been tolerated for at least 4 weeks and more loss is clinically indicated. If side effects held you back, a slower step may help.
Is my compounded semaglutide weaker?
Not necessarily: in Wegovy’s own trials, loss slowed over time too, and those trials didn’t include compounded semaglutide. Compounded semaglutide isn’t FDA-approved or reviewed for quality before it’s sold, so check the strength on your label, its beyond-use date and how it’s been stored. Members can reach us 24/7 at
When should I ask about switching to tirzepatide?
When you’ve leveled off at your highest comfortable dose and still want more change, ask your provider. SURMOUNT-5 compared the brand-name medicines head to head: after 72 weeks, people on tirzepatide (Zepbound) had lost 20.2% on average and people on semaglutide (Wegovy) 13.7%. Compounded versions weren’t part of it, and your provider decides whether a switch fits you.
Does moving up a dose cost more at NexLife?
No: at NexLife, compounded semaglutide is $95 a month on the 12-month plan, or $109 month to month, whatever your dose. If you and your provider choose tirzepatide instead, it’s $115 a month on the 12-month plan, or $129 month to month, also at every dose.
Can I take semaglutide more often to break a plateau?
No, not on your own. Semaglutide is labeled for one shot a week, or one tablet a day, and the FDA has reports of side effects, some serious, that may be related to compounded doses taken more often or raised faster than the label. If you feel it wears off before your next dose, tell your provider.
Is it normal to gain a little while on semaglutide?
Small ups and downs from day to day are common, and one weigh-in doesn’t make a trend. A steady gain over several weeks is worth a check-in. Your provider may look at missed doses, your units, your eating and any new medicines before suggesting a change.
How do you know if you’ve hit a semaglutide plateau?
Look at your weight trend over several weeks, not one weigh-in, and at where you are on the dose schedule. In weeks 1 to 16, the dose is still stepping up, so a stall then often isn’t a plateau; on the Wegovy label, 2.4 mg starts at week 17.
Can a new vial cause a semaglutide plateau?
It can if your units no longer match your dose. Units follow the vial’s strength, so the same number of units can be a different dose. Match your units to the strength on the new label before your next dose, and redo the math with every new label.
Do protein and exercise help with a semaglutide plateau?
They can help. Weight loss on a GLP-1 can take muscle with it: a 2025 joint advisory from four obesity, nutrition and lifestyle medicine groups names muscle and bone loss among the challenges. It lists adequate protein and strength training to preserve lean mass, and names activity, sleep and mental stress among factors that support long-term results.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Label, trials and prices read Nov. 12, 2026.
- How we checked. Dose steps, missed-dose rules and the trial figures come from the Wegovy prescribing information (revised June 2026), read Nov. 12, 2026, with the published STEP 1 and STEP 5 papers and SURMOUNT-5 read the same day. The dosing warning comes from the FDA’s page on unapproved
GLP-1 drugs, and the nutrition priorities from the 2025 joint advisory, both read Nov. 12, 2026. Wegovy’s self-pay prices are NovoCare’s, checked Nov. 12, 2026. Nothing here is a dosing plan for you; your provider makes that call. - Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
Plateaued? Let a provider look at the whole picture.
Answer about 3 minutes of health questions online. A licensed provider decides any change, and every dose is $95 a month on the 12-month plan, or $109 month to month.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Wegovy (semaglutide) injection and tablets, prescribing information, Novo Nordisk (revised June 2026; FDA copy). Read Nov. 12, 2026.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002, abstract. Read November 1, 2026.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. Record read November 1, 2026.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-2091, full text. Read Nov. 12, 2026.
- Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol 2025;13:949-963. Record read October 27, 2026.
- Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025, abstract. Read November 1, 2026.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025. Read Nov. 12, 2026.
- FDA: concerns with unapproved
GLP-1 drugs used for weight loss. Read Nov. 12, 2026 (page current as of Oct. 1, 2026). - Nutritional priorities to support
GLP-1 therapy for obesity: a joint advisory of four groups (The Obesity Society, May 30, 2025). Read Nov. 12, 2026. - NovoCare (Novo Nordisk): Wegovy self-pay prices. Checked Nov. 12, 2026.
- NexLife: pricing, every plan.
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. Read Nov. 12, 2026.
- Eli Lilly and Company. Zepbound (tirzepatide) injection: prescribing information. Revised August 2026. Read Nov. 12, 2026.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Read November 2, 2026.